United States - English - NLM (National Library of Medicine)

norwood packaging ltd. - petrolatum 32.3% - skin protectant - temporarily protects and helps relieve chapped, cracked lips - temporarily protects lips from drying effects of wind and cold weather

United States - English - NLM (National Library of Medicine)

taylor james, ltd. - avobenzone (unii: g63qqf2nox) (avobenzone - unii:g63qqf2nox), homosalate (unii: v06sv4m95s) (homosalate - unii:v06sv4m95s), octinoxate (unii: 4y5p7mud51) (octinoxate - unii:4y5p7mud51), octisalate (unii: 4x49y0596w) (octisalate - unii:4x49y0596w) - avobenzone 3 g in 100 g - uses helps prevent and temporarily protect chafed, chapped, cracked, or windburned skin and/or lips - helps prevent subnurn - if use as directed with other sun pretction measures (see directions), decreases the risk of skin cancer and early skin aging caused by the sun stop use and ask a doctor if rash occurs

United States - English - NLM (National Library of Medicine)

bentley laboratories, llc - oxybenzone (unii: 95oos7ve0y) (oxybenzone - unii:95oos7ve0y), padimate o (unii: z11006cmuz) (padimate o - unii:z11006cmuz) - oxybenzone 0.1275 g in 4.25 g - sunscreen - helps prevent sunburn lips on damaged or broken skin if rash develops

United States - English - NLM (National Library of Medicine)

continental vitamin company inc - oxybenzone (unii: 95oos7ve0y) (oxybenzone - unii:95oos7ve0y), padimate o (unii: z11006cmuz) (padimate o - unii:z11006cmuz) - • helps prevent sunburn lips

Australia - English - Department of Health (Therapeutic Goods Administration)

global medical solutions australia pty limited t/a radpharm scientific - perflutren, quantity: 1.1 mg/ml - injection, suspension - excipient ingredients: sodium chloride; propylene glycol; water for injections; dipalmitoylphosphatidylcholine; n-(methoxy-peg-5000 carbamoyl)-dipalmitoylphosphatidylethanolamine sodium; sodium dipalmitoylphosphatidate; glycerol; dibasic sodium phosphate heptahydrate; monobasic sodium phosphate monohydrate - this medicinal product is for diagnostic use only. definity is indicated for use in patients in contrast-enhanced diagnostic ultrasound imaging to improve the characterization of focal lesions of the liver and kidney. definity is indicated for use in patients with suboptimal echocardiograms to provide opacification of cardiac chambers, improvement of left ventricular endocardial border delineation and assessment of regional wall at both rest and stress.

United States - English - NLM (National Library of Medicine)

tri-coastal design company inc. - octinoxate (unii: 4y5p7mud51) (octinoxate - unii:4y5p7mud51), oxybenzone (unii: 95oos7ve0y) (oxybenzone - unii:95oos7ve0y), dimethicone (unii: 92ru3n3y1o) (dimethicone - unii:92ru3n3y1o) - octinoxate 6 g in 100 g - sunscreen skin protectant - helps prevent sunburn - temporarily protects and relieves chapped lips

United States - English - NLM (National Library of Medicine)

kamins dermatologics inc. - octinoxate (unii: 4y5p7mud51) (octinoxate - unii:4y5p7mud51), oxybenzone (unii: 95oos7ve0y) (oxybenzone - unii:95oos7ve0y), zinc oxide (unii: soi2loh54z) (zinc oxide - unii:soi2loh54z) - octinoxate 75 mg in 1 g - purpose: sunscreen product a soothing treatment balm that helps heal and protect lips from sun, wind and extreme tempera- tures. repairs happed, sore lips with bio-mapletm compound and skin softening oils. also helps prevent the breakout of lip sores with broad spectrum uva/uvb sun screening agents. creates a smoother palette for lipstick application by diminishing the appearance of lip lines and reducing the feathering of lip color. use anytime for fuller, more luscious lips uses helps prevent sunburn higher spf gives more sunburn protection provides moderate protection against sunburn

Malta - English - Medicines Authority

mylan products limited - lipase; amylase; protease - capsule - lipase 10000 u; amylase 8000 u; protease 600 u - digestives, incl. enzymes

Malta - English - Medicines Authority

mylan products limited - lipase; amylase; protease - capsule - lipase 25000 u; amylase 18000 u; protease 1000 u - digestives, incl. enzymes

United States - English - NLM (National Library of Medicine)

vivus llc - pancrelipase lipase (unii: 8myc33932o) (pancrelipase lipase - unii:8myc33932o), pancrelipase amylase (unii: yoj58o116e) (pancrelipase amylase - unii:yoj58o116e), pancrelipase protease (unii: 3560d81v50) (pancrelipase protease - unii:3560d81v50) - pancreaze is indicated for the treatment of exocrine pancreatic insufficiency in adult and pediatric patients. none. risk summary published data from case reports with pancrelipase use in pregnant women have not identified a drug-associated risk of major birth defects, miscarriage or other adverse maternal or fetal outcomes. pancrelipase is minimally absorbed systematically; therefore, maternal use is not expected to result in fetal exposure to the drug. animal reproduction studies have not been conducted with pancrelipase. the background risk of major birth defects and miscarriage for the indicated population is unknown. all pregnancies have a background risk of birth defect, loss, or other adverse outcomes. in the u.s. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2 to 4% and 15 to 20%, respectively. risk summary there are no data on the presence of pancrelipase in either human or animal milk, the effects on the breastfed infant or the effects on milk production. pancrelipase is minimally absorbed systemically following oral administration, therefore maternal use is not expected to result in clinically relevant exposure of breastfed infants to the drug. the developmental and health benefits of breastfeeding should be considered along with the mother's clinical need for pancreaze and any potential adverse effects on the breastfed infant from pancreaze or from the underlying maternal condition. the safety and effectiveness of pancreaze for the treatment of exocrine pancreatic insufficiency have been established in pediatric patients. use of pancreaze for this indication is supported by an adequate and well-controlled trial in adult and pediatric patients 8 to 17 years of age (study 1) along with supportive data from a randomized, investigator-blinded, dose-ranging study in 17 pediatric patients aged 6 to 30 months (study 2). both study populations consisted of patients with exocrine pancreatic insufficiency due to cystic fibrosis. the safety in pediatric patients in these studies was similar to that observed in adult patients [see adverse reactions (6.1) and clinical studies (14)] . dosages exceeding 6,000 lipase units/kg/meal have been reported postmarketing to be associated with fibrosing colonopathy and colonic strictures in pediatric patients less than 12 years of age. if there is a history of fibrosing colonopathy, monitor patients during treatment with pancreaze because some patients may be at risk of progressing to stricture formation. do not exceed the recommended dosage of either 2,500 lipase units/kg/meal, 10,000 lipase units/kg/day, or 4,000 lipase units/g fat ingested/day in pediatric patients greater than 12 months of age without further investigation . [see dosage and administration (2.2)and warnings and precautions (5.1)] . crushing or chewing pancreaze capsules or mixing the capsule contents in foods having a ph greater than 4.5 can disrupt the protective enteric coating on the capsule contents and result in early release of enzymes, irritation of the oral mucosa, and/or loss of enzyme activity. instruct the patient or caregiver of the following: consume sufficient liquids (juice, water, breast milk, or formula) to ensure complete swallowing, and visually inspect the mouth of pediatric patients less than 12 months of age to ensure no drug is retained in the mouth and irritation of the oral mucosa has not occurred [see dosage and administration (2.3)and warnings and precautions (5.2)]. clinical studies of pancreaze did not include sufficient numbers of patients aged 65 years and over to determine whether they respond differently from younger patients. other reported clinical experience has not identified differences in responses between patients aged 65 years and over and younger adult patients.